Economic burden associated with adverse events of special interest in patients with relapsed Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia in the United States
| Autor: | Xue Song, Lorena Lopez-Gonzalez, Krutika Jariwala-Parikh, Xinke Zhang, Ze Cong |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male Oncology medicine.medical_specialty Databases Factual Gastrointestinal Diseases Philadelphia Chromosome Negative Infections Cohort Studies Young Adult 03 medical and health sciences 0302 clinical medicine Cost of Illness Recurrence hemic and lymphatic diseases Internal medicine Humans Medicine Pharmacology (medical) In patient Adverse effect Retrospective Studies Cytopenia business.industry Health Policy Health Care Costs General Medicine B-cell acute lymphoblastic leukemia Middle Aged Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease United States Hospitalization 030220 oncology & carcinogenesis Toxicity Female Lymph business Follow-Up Studies 030215 immunology |
| Zdroj: | Expert Review of Pharmacoeconomics & Outcomes Research. 18:573-580 |
| ISSN: | 1744-8379 1473-7167 |
| DOI: | 10.1080/14737167.2018.1490645 |
| Popis: | Infections, cytopenia, and gastrointestinal (GI) toxicity are adverse events of special interest (AESI) affecting most relapsed Philadelphia chromosome-negative (Ph-) B-cell acute lymphocytic leukemia (ALL) patients. This study quantified real-world rates and economic burden of these events among relapsed Ph- B-cell ALL patients in the United States.Adults with relapsed Ph- B-cell ALL during 1 April 2009-31 October 2016 were selected from MarketScan® healthcare claims databases. Outcomes included proportions of patients with AESIs and AESI-related costs during 100 days after relapsed hospitalization.Of 400 relapsed Ph- B-cell ALL patients, 92.5% experienced ≥1 AESI during the median 100-day follow-up, of which 64.6% had infections, 94.6% cytopenia, and 46.2% GI toxicities. Mean (SD; median) AESI-related total cost per patient during follow-up was $197,213 ($308,551; $105,731), with a mean of 2 AESI-related hospitalizations comprising 32.2 inpatient days. Mean (SD; median) healthcare costs were highest for infections ($164,461 [$347,083; $64,528]), followed by cytopenia ($125,210 [$165,141; $67,475]) and GI events ($11,652 [$40,231; $1349]).The economic burden of AESIs is substantial, with infections the most expensive, followed by cytopenia and GI toxicity. New therapies that can improve outcomes in relapsed Ph- B-cell ALL while offering a favorable safety profile are needed. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|